| Date Filed | Type | Description |
| 10/04/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/07/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/07/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 07/10/2023 |
8-K
| Other Events Interactive Data |
| 06/08/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.9% stake in Elanco Animal Health Incorporated |
| 05/25/2023 |
SD
| Form SD - Specialized disclosure report: |
| 05/19/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/06/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/01/2023 |
8-K/A
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/14/2023 |
SC 13G/A
| DODGE & COX reports a 17.9% stake in Elanco Animal Health Incorporated |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 4% stake in ELANCO ANIMAL HEALTH INC |
| 02/09/2023 |
SC 13G/A
| PRIMECAP MANAGEMENT CO reports a 7% stake in Elanco Animal Health Inc |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 9.6% stake in Elanco Animal Health Inc. |
| 02/01/2023 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/31/2023 |
8-K
| Other Events Interactive Data |
| 01/09/2023 |
8-K
| Investor presentation|
Docs:
|
"© 2023 Elanco or its affiliates This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933 and Sectio n 21E of the Securities Exchange Act of 1934 , including, without limitation , our long - term revenue and earnings growth expectations, reduction of debt and leverage, expectations regarding product launche s and related regulatory proceedings, and our industry and our operations, performance, and financial condition . Forward - looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward - looking statements relate to the fu ture, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that a..." |
|
| 12/22/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 12/09/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/10/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/08/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/08/2022 |
8-K
| Quarterly results |
| 09/09/2022 |
SC 13D/A
| Sachem Head Capital Management LP reports a 6% stake in Elanco Animal Health Incorporated |
| 09/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/29/2022 |
8-K
| Quarterly results |
| 05/26/2022 |
SD
| Form SD - Specialized disclosure report: |
| 05/19/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|